Dipeptidyl Peptidase 4 Inhibitors Market Trends

Dipeptidyl Peptidase 4 Inhibitors Market Trends

• The increasing global prevalence of type 2 diabetes drives the growth of the DPP-4 inhibitors market.
   
• Type 2 diabetes has become more common worldwide due to lifestyle factors such as poor diet, lack of physical activity, and rising obesity rates.
   
• For instance, according to the World Health Organization, approximately 422 million people are affected by diabetes globally, with the majority residing in low- and middle-income countries. Diabetes directly causes about 1.5 million deaths each year, and over 95% of those with diabetes have type 2.
   
• Similarly, as per the Centers for Disease Control and Prevention (CDC), 37.3 million people in the U.S. have diabetes (11.3% of the population), and 96 million adults aged 18 years or older have prediabetes (38.0% of the adult U.S. population).
   
• This rising number of diabetes cases has increased the demand for effective treatment options, including DPP-4 inhibitors, which play a crucial role in comprehensive diabetes management strategies.
   
• Additionally, the preference for oral medications supports the growth of the DPP-4 inhibitors market. Patients often favor oral DPP-4 inhibitors over injectable treatments due to their convenience and ease of use.
   
• According to the National Health and Nutrition Examination Survey (NHANES), the use of DPP-4 inhibitors among adults with type 2 diabetes in the U.S. increased from 0.5% in 2003-2006 to 10.4% in 2015-2018.
   
• The combination of efficacy, safety, and ease of use has led many patients and healthcare providers to favor DPP-4 inhibitors, supporting market growth.